The Impact of Drug-Induced Liver Injury on Drug Development

Having trouble viewing images? View in web browser

GLOBAL CENTRAL LABS SERIES PPD's New Podcast LISTEN TO A NEW COMPLIMENTARY PODCAST ON DRUG-INDUCED LIVER INJURY Listen to the podcast >  /  Contact us > Establishing a diagnosis of drug-induced liver injury (DILI) can be difficult, given the presence of other potential causes of liver injury and no predictive test currently available. Possessing the insight to recognizing it early in clinical trials is vital. Presented by PPD and PharmaVOICE, the podcast, Understanding the Impact of Drug-Induced Liver Injury on Drug Development, features valuable insight into this rare side effect. Hear from Dr. Steve Lobel, PPD's vice president of global laboratory operations, on how to identify DILI and its impact on the global clinical development process. If you would like more in depth information on this topic, you can also download PPD's white paper, Understanding Drug-Induced Liver Injury in the Context of Pharmaceutical Development. For more information about PPD's comprehensive global central labs services, contact us via email or visit us online. Contact PPD Connect with PPD Follow PPD

This email was sent by: PPD, 929 N. Front St., Wilmington, NC 28401-3331 United States. Legal Notices | Privacy Policy

You have received this email because you registered at BioSpace. BioSpace regularly sends emails to active subscribers on behalf of our advertising partners or to promote our own products and services. If you would like to stop receiving all email communications from BioSpace, you can unsubscribe at any time by clicking here. BioSpace 6465 South Greenwood Plaza, Suite 400, Centennial, CO 80111, U.S. (888) BIOSPACE